ERBB2 and breast carcinoma: Seventeen cases of breast cancer organoids with different stages (Figure 1B) and molecular types (Figure 1A) were successfully established: For luminal A (5/9), luminal B (4/5), HER2+ (4/7) and basal‐like (4/7) the success rate of PDOs was approximately 60% (17/28) (Figure 1A), slightly lower than that of previous studies.6, 14, 16